Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1 Oropharyngeal Neoplasms 1 Mouth Neoplasms 1 Lymphoid Interstitial Pneumonia 1 Lip Neoplasms 1 Leukemia, Myeloid, Acute 1 Head and Neck Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cytarabine 197 Azacitidine 143 Cyclophosphamide 136 fludarabine phosphate 112 fludarabine 97 Busulfan 96 venetoclax 95 Mycophenolic Acid 82 Whole-Body Irradiation 81 Tacrolimus 78 Peripheral Blood Stem Cell Transplantation 78 Decitabine 62 Filgrastim 56 Granulocyte Colony-Stimulating Factor 54 Cyclosporine 53 Melphalan 52 Methotrexate 51 Idarubicin 51 Daunorubicin 49 Antilymphocyte Serum 47 Clofarabine 43 Etoposide 41 Thiotepa 35 Gemtuzumab 34 Mitoxantrone 32 Stem Cell Transplantation 31 CPX-351 27 Specimen Handling 25 Radiotherapy 25 thymoglobulin 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Leukemia, Myeloid, Acute × ficlatuzumab × Clear all

NCT04100330 2020-03-31

CyFi2

AVEO Pharmaceuticals, Inc.

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡